ReviewNutrients2021
The Putative Antidepressant Mechanisms of Probiotic Bacteria: Relevant Genes and Proteins.
Review in Nutrients, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06905223 (A Pilot Study on the Efficacy of a Synbiotic Formula), which is not on this map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Pilot Study on the Efficacy of a Synbiotic Formula (MQU10) in Improving Mood and Well-being in Adults With Mild to Moderate Depressive Symptoms
Who cites it
18 citing papers in PubMed.
- GABA production from buckwheat derived probiotics (Cytobacillus oceanisediminis): a promising approach for neurological health enhancement : Buckwheat-Derived Probiotics for Neurological Benefits.International microbiology : the official journal of the Spanish Society for Microbiology · 2026Article
- Bridging Mind and Gut: The Molecular Mechanisms of microRNA, Microbiota, and Cytokine Interactions in Depression.Current gene therapy · 2026Review
- Gut Microbiome as a Source of Probiotic Drugs for Parkinson's Disease.International journal of molecular sciences · 2025Review
- Exploring the Potential of Probiotics and Prebiotics in Major Depression: From Molecular Function to Clinical Therapy.Probiotics and antimicrobial proteins · 2024Review
- Human Gut Microbiota for Diagnosis and Treatment of Depression.International journal of molecular sciences · 2024Review
- The effect of psychoactive bacteria, Bifidobacterium longum Rosell®-175 and Lactobacillus rhamnosus JB-1, on brain proteome profiles in mice.Psychopharmacology · 2024Article
- The use of omics technologies in creating LBP and postbiotics based on theFrontiers in microbiology · 2024Article
- Unveiling the Connection between Microbiota and Depressive Disorder through Machine Learning.International journal of molecular sciences · 2023Article
- Metabolites Potentially Determine the High Antioxidant Properties ofBiotech (Basel (Switzerland)) · 2023Article
- The Role of Probiotics and Their Metabolites in the Treatment of Depression.Molecules (Basel, Switzerland) · 2023Review
- A Microbial-Based Approach to Mental Health: The Potential of Probiotics in the Treatment of Depression.Nutrients · 2023Review
- New Insights into the Gut Microbiota in Neurodegenerative Diseases from the Perspective of Redox Homeostasis.Antioxidants (Basel, Switzerland) · 2022Review
- Lactobacilli: Legal Regulation and Prospects for New Generation Drugs.Applied biochemistry and microbiology · 2022Article
- Mechanisms of Cognitive Impairment in Depression. May Probiotics Help?Frontiers in psychiatry · 2022Review
- Sodium Butyrate Protects Against Ethanol-Induced Toxicity in SH-SY5Y Cell Line.Neurotoxicity research · 2021Article
- Biomarkers and Utility of the Antioxidant Potential of Probiotic Lactobacilli and Bifidobacteria as Representatives of the Human Gut Microbiota.Biomedicines · 2021Review
- The Role of the PFNA Operon of Bifidobacteria in the Recognition of Host's Immune Signals: Prospects for the Use of the FN3 Protein in the Treatment of COVID-19.International journal of molecular sciences · 2021Review
- Common Inflammatory Mechanisms in COVID-19 and Parkinson's Diseases: The Role of Microbiome, Pharmabiotics and Postbiotics in Their Prevention.Journal of inflammation research · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Probiotic bacteria are widely accepted as therapeutic agents against inflammatory bowel diseases for their immunostimulating effects. In the last decade, more evidence has emerged supporting the positive effects of probiotics on the course of neurodegenerative and psychiatric diseases. This brief review summarizes the data from clinical studies of probiotics possessing antidepressant properties and focuses on the potential genes and proteins underlying these mechanisms. Data from small-sample placebo-controlled pilot studies indicate that certain strains of bacteria can significantly reduce the symptoms of depression, especially in depressed patients. Despite the disparity between studies attempting to pinpoint the bacterial putative genes and proteins accounting for these mechanisms, they ultimately show that bacteria are a potential source of metabiotics-microbial metabolites or structural components. Since the constituents of cells-namely, secreted proteins, peptides and cell wall components-are most likely to be entangled in the gut-brain axis, they can serve as starting point in the search for probiotics with concrete properties.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.